All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-10-04T13:30:12.000Z

Current systemic treatments for nail psoriasis

Oct 4, 2023
Share:
Learning objective: After reading this article, learners will be able to cite the latest data for treatments of nail psoriasis.

Bookmark this article

Nail psoriasis is a common manifestation in patients with psoriasis and psoriatic arthritis (PsA), affecting up to 60% of patients with psoriasis and ~80% of patients with PsA.1 Nail psoriasis is associated with lower quality of life in patients with psoriatic disease, and can be predictive of PsA development.1 The understanding of nail psoriasis is limited, due to a lack of clinical trials focused on this manifestation.2 Therefore, available treatment data of nail psoriasis have been generated from clinical trials investigating psoriasis and PsA. Here, we present the currently available systemic treatments for nail psoriasis.

Pathogenesis1

In nail psoriasis, inflammation of the nail bed or matrix occurs, resulting in morphological changes. Nail psoriasis is also associated with enthesitis, which can be an early indicator of PsA and can suggest increased disease severity. In nail psoriasis, the nail bed can become discolored, with salmon patches, splinter hemorrhages, and onycholysis also occurring. The nail matrix can become pitted, with leukonychia, Beau lines, and nail crumbling.

Diagnosis1

Nail psoriasis is diagnosed by the presence of psoriatic changes in the nail. In patients with psoriatic disease, nail manifestations should be monitored continuously, as they can be a predictor of disease evolution. In the clinical trial setting, the Nail Psoriasis Severity Index (NAPSI) is used as a tool to assess nail psoriasis. With the NAPSI, each nail is divided into quadrants and scored for presence or absence of psoriatic changes (1 for presence and 0 for absence), with the scores added together to obtain a total NAPSI score, as shown in Figure 1. A modified NAPSI (mNAPSI) can also be used, which measures disease severity in each nail, but this can be difficult to carry out in a real-world setting. Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) can also be used to assess nail psoriasis, with a PGA-F score 3 indicating moderate-to-severe nail psoriasis.

Figure 1. NAPSI score and common symptoms of nail psoriasis* 

NAPSI, Nail Psoriasis Severity Index.
*Data from Kirkham, et al.1 Created with Biorender.com

Treatments2

There are multiple treatments available for patients with nail psoriasis. Treatment are selected based on disease severity, comorbidities, and extent of skin and joint involvement. Topical and injectable therapies are usually used in patients where only a few nails are involved, with systemic therapies used when nail psoriasis is severe. Table 1, Table 2, and Table 3 provide an overview of tumor necrosis factor alpha inhibitors,2,3,4,5 interleukin inhibitors, and other systemic therapies currently being used or investigated for nail psoriasis.

Table 1. TNF-a inhibitors used for the treatment of nail psoriasis*

Therapy2

FDA Approved?3,4

Efficacy2

Etanercept

PsO and PsA

Showed efficacy in treating NP in multiple clinical trials.

Infliximab

PsO and PsA

Shown to significantly improve nail involvement in patients with psoriasis in the phase III EXPRESS trial (NCT00106834).

Adalimumab

PsO and PsA

Well tolerated, with improvements to NAPSI score observed in a phase III study.

Certolizumab

PsO and PsA

SC administration showed efficacy in a real-life multicenter study.

Golimumab

PsA, rheumatoid arthritis, ankylosing spondylitis

Improvements in mNAPSI score observed in treating NP associated with PsA.

mNAPSI, Modified Nail Psoriasis Severity Index; NAPSI, Nail Psoriasis Severity Index; NP, nail psoriasis; PsA, psoriatic arthritis; PsO, psoriasis; SC, subcutaneous; TNF-a, tumor necrosis factor alpha.
*Adapted from Battista, et al.2 and Drugs.com3,4


Table 2. IL inhibitors used for the treatment of nail psoriasis*

Therapy2

FDA Approved?3,4

Efficacy2

Ustekinumab

PsO and PsA

Showed improvements in NAPSI score in both finger and toenail psoriasis; however, some trials suggest more marked improvements in the nails of the big and 2nd toes.

Ixekizumab

PsO and PsA

Showed efficacy in treating NP and greater complete nail clearance when compared with etanercept in UNCOVER-2 and -3 (NCT01597245; NCT01646177)

Secukinumab

PsO and PsA

Showed sustained efficacy in treating NP for up to 2.5 years in the TRANSFIGURE trial (NCT01807520)

Brodalumab

PsO

Brodalumab showed an improved mean NAPSI score over ustekinumab in the AMAGINE-2 and -3 trials.

Bimekizumab

Showed better efficacy compared to placebo in the BE COMPLETE (NCT03896581) clinical trial at 16 weeks.

Guselkumab

PsO and PsA

Positive NAPSI score and F-PGA responses at Week 16 in VOYAGE 1 and 2 (NCT02207231; NCT02207244)

Risankizumab

PsO and PsA

In the KEEPsAKE1 (NCT03675308) trial, risankizumab treatment led to significant improvements in nail outcomes versus placebo in patients with NP.

Tildrakizumab

PsO

No RCTs evaluating efficacy in nail disease. Some real-life experiences suggest it can improve NAPSI scores.

F-PGA, Physician Global Assessment of Fingernail Psoriasis; NAPSI, Nail Psoriasis Severity Index; NP, nail psoriasis; PsA, psoriatic arthritis; PsO, psoriasis; RCT, randomized controlled trial.

*Adapted from Battista, et al.2 and Drugs.com3,4


Table 3. Other therapies used for the treatment of nail psoriasis*

Therapy2

FDA Approved?3,4,5

Efficacy2

Acitretin

PsO

Case studies suggest it can improve NP, but another study reported worsening of NP after acitretin.

Methotrexate

PsO

In the METOP trial (NCT02902861), NP improved in some patients, although the improvement was slow.

Cyclosporine

PsO

Studies show that cyclosporine has efficacy in treating NP; however, improvements may be greater when combined with a TNF-a inhibitor.

Dimethylfumarate

PsO

Led to improvements in NP from baseline in the SKILL study.

Phototherapy/

photochemotherapy

PsO

Studies have shown the nail plate completely blocks UVB radiation, and mostly blocks UVA, so phototherapy has low efficacy in NP.

Apremilast

PsO and PsA

Apremilast improved NAPSI scores in NP in the ESTEEM 1 and 2 trials (NCT01194219; NCT01232283) from baseline to 16 weeks.

NAPSI, Nail Psoriasis Severity Index; NP, nail psoriasis; PsA, psoriatic arthritis; PsO, psoriasis; TNF-a, tumor necrosis factor alpha; UVA, ultraviolet A; UVB, ultraviolet B.

*Adapted from Battista, et al.2, Drugs.com3,4, and the National Psoriasis Foundation.5

Conclusion 

Nail involvement in patients with psoriasis can be predictive of the severity of disease, and can lead to lower quality of life.1 Therefore, prompt treatment for nail psoriasis is important.1 There are multiple systemic treatments available which have shown efficacy in treating nail psoriasis, and treatment should be chosen based on patient characteristics, disease severity, joint involvement, and available guidelines.2 Additional studies, to compare efficacy and safety of treatments in nail psoriasis specifically, will improve knowledge and treatment options for these patients.

  1. Kirkham BW, Egeberg A, Behrens F, et al. A comprehensive review of ixekizumab efficacy in nail psoriasis from clinical trials for moderate-to-severe psoriasis and psoriatic arthritis. Rheumatol Ther. 2023;10(5):1127-114 DOI: 10.1007/s40744-023-00553-1
  2. Battista T, Scalvenzi M, Martora F, et al. Nail psoriasis: an updated review of currently available systemic treatments. Clin Cosmet Investig Dermatol. 2023;16:1899-1932. DOI: 2147/CCID.S417679
  3. Drugs.com. What are the new drugs for plaque psoriasis? https://www.drugs.com/medical-answers/new-drugs-treatment-plaque-psoriasis-3511670/ Updated May 25, 2023. Accessed Sept 19, 2023.
  4. Drugs.com. Medications for Psoriatic Arthritis. https://www.drugs.com/condition/psoriatic-arthritis.html Accessed Sept 19, 2023.
  5. National Psoriasis Foundation. Phototherapy. https://www.psoriasis.org/phototherapy/ Accessed Sept 20, 2023.

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox